| Title |
A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, April 2013
|
| DOI | 10.1007/s00280-013-2163-4 |
| Pubmed ID | |
| Authors |
Robert Amato, Mika Stepankiw, Patricia Gonzales |
| Abstract |
Long-term hormonal ablation in prostate cancer is associated with decreased overall health and quality of life. Few reports emphasized the role of chemotherapy in the management of early stage prostate cancer. This study analyzed the safety and efficacy of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for patients identified as local failures or not eligible for prostatectomy or radiation therapy due to advanced disease presentation. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| China | 1 | 2% |
| Unknown | 45 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 22% |
| Student > Doctoral Student | 7 | 15% |
| Student > Ph. D. Student | 7 | 15% |
| Other | 5 | 11% |
| Researcher | 5 | 11% |
| Other | 10 | 22% |
| Unknown | 2 | 4% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 46% |
| Computer Science | 4 | 9% |
| Agricultural and Biological Sciences | 4 | 9% |
| Nursing and Health Professions | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Other | 8 | 17% |
| Unknown | 4 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 April 2013.
All research outputs
#14,065,859
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#1,735
of 2,501 outputs
Outputs of similar age
#108,240
of 199,082 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#12
of 29 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,082 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.